US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Agenus Inc. - Common Stock (NQ:AGEN)

8.360 +0.030 (+0.36%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Agenus Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
Agenus Announces Botensilimab and Balstilimab Presentations at ASCO 2025
From Agenus Inc.
Via Business Wire
News headline image
Here are the top movers in Tuesday's session. ↗
Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
News headline image
Agenus to Present New BOT/BAL Data in Two Presentations at AACR 2025
From Agenus Inc.
Via Business Wire
News headline image
Earnings Scheduled For November 12, 2024 ↗
 
Via Benzinga
News headline image
Insights Ahead: Agenus's Quarterly Earnings ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 12, 2025 ↗
 
Via Benzinga
News headline image
Agenus's Earnings: A Preview ↗
 
Via Benzinga
News headline image
Agenus to Provide Corporate Update and First Quarter 2025 Financial Report
From Agenus Inc.
Via Business Wire
News headline image
Agenus’ BOT/BAL Neoadjuvant Pan-Cancer Data from the NEOASIS Study Presented in an Oral Session at AACR
From Agenus Inc.
Via Business Wire
News headline image
Agenus’ BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025
From Agenus Inc.
Via Business Wire
News headline image
Agenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment Innovation
From Agenus Inc.
Via Business Wire
News headline image
Agenus (AGEN) Q4 2024 Earnings Call Transcript ↗
AGEN earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program
From Agenus Inc.
Via Business Wire
News headline image
Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications
From Agenus Inc.
Via Business Wire
News headline image
Earnings Scheduled For March 11, 2025 ↗
 
Via Benzinga
News headline image
Agenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor Conference
From Agenus Inc.
Via Business Wire
News headline image
Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report
From Agenus Inc.
Via Business Wire
News headline image
Agenus Presents New Botensilimab/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting
From Agenus Inc.
Via Business Wire
News headline image
CORRECTING and REPLACING Agenus’ BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting
From Agenus Inc.
Via Business Wire
News headline image
Agenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic Sarcomas
From Agenus Inc.
Via Business Wire
News headline image
Agenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease
From Agenus Inc.
Via Business Wire
News headline image
Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers
From Agenus Inc.
Via Business Wire
News headline image
Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs
From Agenus Inc.
Via Business Wire
News headline image
Agenus Gets $22M Mortgage, Plans Strategic Realignment To Focus On Colorectal Cancer Drug Development ↗
Agenus secures a $22M mortgage and announces a strategic realignment to focus on botensilimab/balstilimab in MSS colorectal cancer. 
Via Benzinga
News headline image
Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment
From Agenus Inc.
Via Business Wire
News headline image
Agenus (AGEN) Q3 2024 Earnings Call Transcript ↗
AGEN earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
Agenus Reports Third Quarter 2024 Financial Results and Strategic Advancements in BOT/BAL Development
From Agenus Inc.
Via Business Wire
News headline image
Agenus to Present Compelling Data on Botensilimab and AGEN1721 at SITC 2024
From Agenus Inc.
Via Business Wire
News headline image
Agenus to Provide Third Quarter 2024 Financial Report and Corporate Update
From Agenus Inc.
Via Business Wire
News headline image
DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors of Agenus to Contact Us to Have Their Losses Evaluated Today
From Faruqi & Faruqi LLP
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >